EUVIMEDEUVIMED entdecken
Crossref

The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient

Atsushi Hiraoka, Masatoshi Kudo, Toshifumi Tada, Takeshi Hatanaka, Satoru Kakizaki, Kazuya Kariyama, Hideko Ohama, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Hidenori Toyoda und 36 weitere

Oncology · 2025

DOI: 10.1159/000543405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Atsushi Hiraoka und 47 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan, hirage@m.ehime-u.ac.jp. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, alpha-Fetoproteins, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Rapid development of systemic treatments has resulted in improved prognosis for unresectable hepatocellular carcinoma (uHCC) patients. Since immune therapy shows a favorable therapeutic efficacy, use of tumor markers as biomarkers for monitoring treatment response is necessary. This study aimed to elucidate changes in positive rates of 3 available tumor markers in Japan, including alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), and lens culinaris agglutinin-reactive AFP (AFP-L3) in uHCC patients treated with systemic therapies over time.

Methods

From 2009 to 2023, 1,470 uHCC patients with data of tumor markers before starting treatment were enrolled. The positivity cutoff value for AFP was 20 ng/mL, for AFP-L3 was 10%, and for DCP was 40 mAU/mL. After dividing the 15 years examined into three periods of 5 years each (period I, II, and III), clinical features of the enrolled patients were evaluated, retrospectively.

Results

The percentage of Barcelona Clinic Liver Cancer stage B patients who received systemic therapy increased from period I to III (27.7%, 38.5%, 46.6%, respectively, p < 0.001), which was also seen for HCC patients with a nonviral etiology (alcohol and others) (29.9%, 39.7%, 49.6%, respectively p < 0.001). Positive rates for AFP (67.8%, 62.1%, 50.8%, respectively) and DCP (84.1%, 80.5%, 72.7%, respectively) were decreased (each p < 0.001), while the AFP-L3 rate did not show a significant change (54.4%, 57.7%, 51.9%, respectively, p = 0.390). Among the AFP-negative patients, the rate of positive for DCP or AFP-L3 was increased (24.4%, 28.1%, 35.4%, respectively, p = 0.002).

Conclusion

Based on introduction of systemic treatment in an early stage and increasing numbers of HCC cases with a nonviral etiology, the positive rate of AFP level has been declining. Thus, determination of DCP and AFP-L3 in addition to AFP as markers should be more actively utilized in clinical practice, as well as clinical trials for monitoring and evaluating treatment response in this era of combination immunotherapy as a powerful treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver Neoplasmsalpha-FetoproteinsBiomarkers, TumorImmunotherapyProtein PrecursorsHumansMaleFemaleMiddle AgedAgedProthrombinRetrospective StudiesPrognosisAdultJapanBiomarkersPlant Lectins

Stichwörter der Autor:innen

Alpha-fetoproteinDes-gamma-carboxy prothrombinHepatocellular carcinomaImmune checkpoint inhibitorLens culinaris agglutinin-reactive alpha-fetoprotein

Substanzen

alpha-FetoproteinsBiomarkers, TumoracarboxyprothrombinProthrombinProtein PrecursorsAFP protein, humanlentil lectinBiomarkersPlant Lectins

Autor:innen und Institutionen

  • Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan, hirage@m.ehime-u.ac.jp.
  • Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
  • Department of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Japan.
  • Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.

Zitieren

APA

Hiraoka, A., Kudo, M., Tada, T., Hatanaka, T., Kakizaki, S., Kariyama, K., Ohama, H., Tsuji, K., Ishikawa, T., Takaguchi, K., Itobayashi, E., Toyoda, H., Matono, T., Yata, Y., Ogawa, C., Naganuma, A., Tani, J., Atsukawa, M., Nishimura, T., …, & Kumada, T. (2025). The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient. Oncology. https://doi.org/10.1159/000543405

Vancouver

Hiraoka A, Kudo M, Tada T, Hatanaka T, Kakizaki S, Kariyama K, et al. The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient. Oncology. 2025. doi:10.1159/000543405

BibTeX
@article{Hiraoka2025,
  author = {Hiraoka, Atsushi and Kudo, Masatoshi and Tada, Toshifumi and Hatanaka, Takeshi and Kakizaki, Satoru and Kariyama, Kazuya and Ohama, Hideko and Tsuji, Kunihiko and Ishikawa, Toru and Takaguchi, Koichi and Itobayashi, Ei and Toyoda, Hidenori and Matono, Tomomitsu and Yata, Yutaka and Ogawa, Chikara and Naganuma, Atsushi and Tani, Joji and Atsukawa, Masanori and Nishimura, Takashi and Tajiri, Kazuto and Kawata, Kazuhito and Kosaka, Hisashi and Kuroda, Hidekatsu and Hirooka, Masashi and Nishikawa, Hiroki and Tada, Fujimasa and Nakamura, Shinichiro and Kanayama, Yuki and Nouso, Kazuhiro and Tanaka, Hironori and Tanaka, Kazunari and Imai, Michitaka and Tsutsui, Akemi and Nagano, Takuya and Aoki, Tomoko and Koshiyama, Yuichi and Morishita, Asahiro and Itokawa, Norio and Okubo, Tomomi and Arai, Taeang and Fukunishi, Shinya and Noritake, Hidenao and Nakamura, Yoshiko and Yoshida, Osamu and Enomoto, Hirayuki and Kaibori, Masaki and Hiasa, Yoichi and Kumada, Takashi},
  title = {The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient},
  journal = {Oncology},
  year = {2025},
  doi = {10.1159/000543405}
}
Kostenlos starten →